Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Pre-Publication Trial Results Demonstrate Safety and Effectiveness of CyberKnife Prostate Cancer Treatment

April 30, 2013 By the Associated Press

DENVER–(BUSINESS WIRE)–Apr 30, 2013–Pre-publication results from a national clinical trial show that prostate cancer treatment with CyberKnife® robotic radiosurgery demonstrated excellent preservation of sexual health and resulted in no significant side effects or complications.

“This is great news for men in the Denver metro area and around the nation seeking a non-invasive alternative to surgery, radioactive seed implant or traditional radiation therapy treatments,” said Anova Cancer Care Medical Director and Chief Radiosurgeon Gregg Dickerson, M.D., F.A.C.R. “These results are highly encouraging, and we’re looking forward to their publication.” The results presented at the recent Radiosurgery Society ™ 2013 Scientific Meeting represent the first Medicare-mandated annual report for the Multi-Institutional Registry for Prostate Cancer Radiosurgery (RPCR) trial. RPCR is a long-term, prospective, observational study involving 37 community and academic institutions in 15 states. The ongoing study examined overall survival and quality of life for men treated with Stereotactic Body Radiation Therapy (SBRT) using the CyberKnife robotic surgery platform.

The RPCR trial currently includes more than 1,300 patients diagnosed with early- to intermediate-risk prostate cancer, and Anova Cancer Care is one of the leading CyberKnife centers from around the nation participating in the trial.

“Several factors make this study particularly important,” Dickerson said. “It is multi-institutional, has enrolled large numbers of patients, and is demonstrating the long-term safety and efficacy of robotic SBRT for prostate cancer.” Dickerson has enrolled more than 320 patients in the registry, the largest number of patients contributed to the RPCR registry by a single physician. RPCR early outcome data show: 1. Excellent and durable biochemical response to treatment 2. The local control of disease is equal to any other treatment modality 3. No significant side effects or complications are occurring after treatment 4. Greater than 80% preservation of erectile function 5. Men are very satisfied with this form of treatment Researchers reported excellent preservation of sexual health and little in the way of any late urinary problems or bowel toxicity. Post-procedure PSA scores were comparable to other forms of treatment.

Anova Cancer Care is also currently participating in a landmark national prostate cancer study comparing CyberKnife to several other types of treatment. Results are expected in 2014.

Since 2001, CyberKnife clinics nationwide have successfully treated more than 100,000 patients, and Anova Cancer Care was among the first to start treating prostate patients in Colorado. Dickerson recently assisted in the effort to educate Medicare to gain recognition of CyberKnife as a covered treatment option for prostate cancer in the four-state region that includes Colorado. As of April 2013, Anova Cancer Care has treated more than 400 men for prostate cancer with CyberKnife SBRT.

For more information, visit www.AnovaCancerCare.com or call 303-396-1419. Anova Cancer Care is on Facebook at www.facebook.com/AnovaCancerCare and on Twitter as @AnovaCancerCare.

About Anova Cancer Care
Anova Cancer Care serves Denver and the Rocky Mountain region with the world’s only robotic radiosurgery system designed to treat tumors anywhere in the body. Used by the nation’s leading hospitals and medical centers, the CyberKnife ® System uses continual image guidance technology and computer-controlled robotic mobility to track, detect and correct for tumor and patient movement in real-time throughout the treatment. For prostate cancer, the CyberKnife System enables delivery of high-dose radiation with pinpoint precision, which preserves sexual function, minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames. Anova Cancer Care also treats lung, brain, spine and other cancers with fewer treatments and shorter overall treatment time than surgical or other older forms of radiation therapy alternatives. For more information, visit or call 303-396-1419.

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech